rs12191877 — HLA-C Tag for *06:02

HLA-C*06:02 — The Psoriasis Gatekeeper and Treatment Guide

HLA-C¹¹ HLA-C
Human leukocyte antigen C is a class I MHC gene encoding a cell-surface protein that presents intracellular peptides to CD8+ T cells, allowing the immune system to distinguish self from non-self and from infected or aberrant cells sits at the heart of the psoriasis story. The rs12191877 SNP is a tag variant²² tag variant
A tag SNP doesn't cause disease itself but travels in tight linkage disequilibrium with the functional allele due to shared inheritance, serving as a reliable marker for it for the HLA-C*06:02 allele (historically called HLA-Cw6), the most strongly replicated genetic risk factor for psoriasis ever identified. Unusually for a common disease, this single allele accounts for roughly 35-50% of the genetic contribution³³ 35-50% of the genetic contribution
PSORS1 locus on chromosome 6p21.3 explains the majority of genetic variance in psoriasis; HLA-C*06:02 is the primary susceptibility variant within PSORS1 to disease risk—far exceeding the contribution of any other locus.

The Mechanism

Psoriasis is now understood to be a primary autoimmune disease directed against melanocytes⁴⁴ autoimmune disease directed against melanocytes
Melanocytes are the pigment-producing cells of the epidermis; in psoriasis, CD8+ T cells attack them through HLA-C*06:02-restricted antigen presentation—not merely an inflammatory skin condition. HLA-C*06:02 presents the melanocyte-derived peptide ADAMTSL5⁵⁵ ADAMTSL5
ADAMTS-like protein 5, a secreted glycoprotein expressed specifically in melanocytes; when processed and presented by HLA-C*06:02, it triggers a CD8+ T cell response that drives psoriatic inflammation to CD8+ T cells in the epidermis, triggering the signature IL-17A-driven inflammatory cascade that leads to keratinocyte hyperproliferation and the characteristic scaly plaques. The ERAP1⁶⁶ ERAP1
Endoplasmic reticulum aminopeptidase 1; trims peptides before loading onto HLA class I molecules. ERAP1 variants affect how much ADAMTSL5 peptide is generated for HLA-C*06:02 presentation aminopeptidase controls the supply of this autoantigenic peptide, explaining the well-documented epistatic interaction between HLA-C and ERAP1 variants in psoriasis GWAS.

The gene-dose effect is biologically meaningful. Heterozygous carriers express HLA-C*06:02 on fewer antigen-presenting cells than homozygotes, generating a weaker and less sustained T-cell response. This produces the graded risk seen clinically: homozygotes have substantially higher lifetime risk and earlier onset than heterozygotes.

The Evidence

Feng et al.⁷⁷ Feng et al.
Feng BJ et al. Multiple loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet. 2009;5(8):e1000606 performed a large GWAS identifying rs12191877 as the most significant single SNP (OR 2.92, p=3×10⁻⁵³), but demonstrated that imputed HLA-Cw*0602 dosage showed even stronger association (OR 3.85, p=8×10⁻⁶¹), confirming rs12191877 as a tag for the true causal allele rather than the functional variant itself.

Strange et al.⁸⁸ Strange et al.
Strange A et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985-990 extended this with 2,622 cases and 5,667 controls from the UK and Ireland, identifying the related tag rs10484554 at OR 4.66 (p=4×10⁻²¹⁴)—among the strongest single-variant associations documented in common disease GWAS. The same study demonstrated the epistatic interaction: ERAP1 variants only influenced psoriasis risk in HLA-C risk allele carriers⁹⁹ ERAP1 variants only influenced psoriasis risk in HLA-C risk allele carriers
Stratified analysis showed ERAP1 OR 1.43 in HLA-C risk carriers vs. no effect in non-carriers, combined p=6.95×10⁻⁶.

The clinical phenotype data are striking. Chen and Tsai¹⁰¹⁰ Chen and Tsai
Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854-862 reviewed decades of studies showing that HLA-Cw6 (HLA-C*06:02) consistently associates with type I early-onset psoriasis (peak ages 18-22), guttate morphology, Koebner phenomenon, positive family history, and reduced nail involvement compared to HLA-Cw6-negative disease. In populations studied for guttate psoriasis specifically, HLA-Cw6 prevalence reaches 73-100% of affected individuals.

The streptococcal trigger connection is also HLA-dependent. Mallbris et al.¹¹¹¹ Mallbris et al.
Mallbris L et al. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis. BMC Dermatol. 2009;9:5 found that HLA-Cw*0602-positive patients showed twice the rate of positive streptococcal throat cultures at disease onset (OR 3.5 for guttate, OR 2.3 for plaque psoriasis), consistent with molecular mimicry between streptococcal and skin antigens.

Practical Actions

The most actionable implication of HLA-C*06:02 status is biologic selection. Dand et al.¹²¹² Dand et al.
Dand N et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120-2130 analyzed 1,326 patients receiving adalimumab or ustekinumab and found that HLA-C*06:02-negative patients responded significantly better to adalimumab than ustekinumab at all timepoints (OR 2.95 at 6 months; OR 5.98 in those with concomitant psoriatic arthritis). HLA-C*06:02-positive patients without psoriatic arthritis showed poorer adalimumab response at 12 months. For ustekinumab specifically, Van Vugt et al.¹³¹³ Van Vugt et al.
Van Vugt LJ et al. Association of HLA-C*06:02 status with differential response to ustekinumab. JAMA Dermatol. 2019;155(6):708-715 confirmed in a meta-analysis of 8 studies (1,048 patients) that HLA-C*06:02-positive patients achieve 89% vs. 62% PASI75 response at 6 months. Secukinumab (anti-IL-17A) efficacy is high regardless of HLA-C*06:02 status, making it a reasonable choice for either genotype.

For TT homozygotes in particular, the elevated lifetime risk warrants dermatology awareness, prompt evaluation when skin changes appear, and advance discussion of treatment options before disease becomes severe.

Interactions

The documented ERAP1 epistasis is the most important gene-gene interaction here. ERAP1 risk haplotypes (particularly Hap2) compound the psoriasis risk in HLA-C*06:02 carriers by generating more autoantigenic ADAMTSL5 peptide for HLA-C*06:02 presentation. ERAP1 protective haplotypes (Hap10) reduce melanocyte immunogenicity even in HLA-C*06:02 carriers. This interaction explains why not all HLA-C*06:02 carriers develop psoriasis. At the population level, the GWAS-defined epistasis is confined largely to disease onset between ages 10-20, suggesting genetic heterogeneity within childhood-onset psoriasis. rs2187668 (HLA-DQA1 — DQ2.5 tag) shares the same chromosomal region on 6p21, reflecting the complex multi-locus HLA architecture governing multiple immune-mediated diseases at this locus.